CLINICAL TRIALS PROFILE FOR NORVASC
✉ Email this page to a colleague
All Clinical Trials for NORVASC
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00125463 ↗ | Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients | Unknown status | The Japanese Society of Hypertension | Phase 3 | 2001-09-01 | The purpose of this study is to compare an angiotensin II receptor antagonist (candesartan cilexetil- Blopress®) and a calcium channel blocker (amlodipine besilate- Norvasc®/Amlodin®) in terms of the incidence of cardiovascular events among high-risk hypertensive patients. |
| NCT00281580 ↗ | Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension | Completed | Boehringer Ingelheim | Phase 3 | 2006-04-01 | To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pre ssure. |
| NCT00294567 ↗ | Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J) | Completed | Japan Heart Foundation | Phase 4 | 2005-12-01 | In patients with hypertension who undergo elective PCI, the effects of long-term administration of Calblock (azelnidipine) on plaque volume will be determined quantitatively by 3D-IVUS and compared with those of amlodipine besilate (Norvasc or Amlodin). |
| NCT00294567 ↗ | Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J) | Completed | Juntendo University | Phase 4 | 2005-12-01 | In patients with hypertension who undergo elective PCI, the effects of long-term administration of Calblock (azelnidipine) on plaque volume will be determined quantitatively by 3D-IVUS and compared with those of amlodipine besilate (Norvasc or Amlodin). |
| NCT00294567 ↗ | Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J) | Completed | Juntendo University Hospital | Phase 4 | 2005-12-01 | In patients with hypertension who undergo elective PCI, the effects of long-term administration of Calblock (azelnidipine) on plaque volume will be determined quantitatively by 3D-IVUS and compared with those of amlodipine besilate (Norvasc or Amlodin). |
| NCT00412113 ↗ | A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk | Completed | Pfizer | Phase 4 | 2007-01-01 | The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood pressure and low density lipoprotein cholesterol (LDL-C) goals compared with a Joint National Committee 7/ National Cholesterol Education Program Adult Treatment Panel III (JNC 7/NCEP ATP III) guideline-based approach (Norvasc plus TLC regimen) after 6 weeks of treatment in primary prevention subjects with hypertension and additional risk factors, including dyslipidemia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NORVASC
Condition Name
Clinical Trial Locations for NORVASC
Trials by Country
Clinical Trial Progress for NORVASC
Clinical Trial Phase
Clinical Trial Sponsors for NORVASC
Sponsor Name
